VITRAKVI (larotrectinib) capsules

Vitrakvi is a cancer medicine for treating solid tumours with NTRK gene fusion. NTRK gene fusion is a rare genetic abnormality that can occur in tumours from different parts of the body such as the lungs, thyroid glands and intestines.Brand Name: VITRAKVI (larotrectinib) capsules, for oral use, VITRAKVI® (larotrectinib) oral solution Initial U.S. Approval: 2018

Home | larotrectinib capsules

VITRAKVI (larotrectinib) capsules Price In India
VITRAKVI (larotrectinib) capsules, for oral use

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

VITRAKVI (larotrectinib) capsules, for oral use

Larotrectinib sulfate is approved to treat: Solid tumors that have an NTRK gene fusion without a drug-resistance mutation in certain TRK proteins.

VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.

Larotrectinib is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. Larotrectinib was the first drug to be specifically developed and approved to treat any cancer containing certain mutations, as opposed to cancers of specific tissues (i.e., the approval is “tissue agnostic”). Larotrectinib was approved for medical use in the European Union in September 2019.[16][17] It was approved for medical use in Australia in August 2020.

Drug (Brand / Generic): VITRAKVI / larotrectinib
Current Indications: solid tumours with NTRK gene fusion
Marketed by:: Bayer HealthCare
Approval Date: 2018

Capsules: 25 mg, 100 mg, Oral Solution: 20 mg/mL.

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.